HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4- (3- (2- propyl- 3- hydroxy- 4- acetyl)phenoxy)propyloxyphenoxy acetic acid

a PPAR-delta agonist has regulatory effects on a variety of adipokines, and these effects might explain some of their metabolic function.

Also Known As:

L 165041; L-165041

Networked: 12 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Glycolates
      - Phenoxyacetates: 2
        4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: 12
  - Acyclic Acids
    - Acetates: 4994
      - Glycolates
        Phenoxyacetates: 2
        4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid: 12

Experts

1.	Lee, Kuy-Sook: 4 articles (06/2012 - 02/2009)
2.	Lim, Hyun-Joung: 4 articles (06/2012 - 02/2009)
3.	Park, Hyun-Young: 4 articles (06/2012 - 02/2009)
4.	Park, Jin-Hee: 4 articles (06/2012 - 02/2009)
5.	Lee, Seahyoung: 3 articles (11/2009 - 02/2009)
6.	Choi, Hye-Eun: 2 articles (11/2009 - 02/2009)
7.	Wahli, Walter: 2 articles (08/2005 - 03/2005)
8.	Kim, Hanna: 1 article (06/2012)
9.	Kwak, Hyun-Jeong: 1 article (06/2012)
10.	Chen, C-T: 1 article (08/2011)

Related Diseases

1.	Inflammation (Inflammations) 11/10/2009 - "PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice." 08/01/2005 - "Conversely, wild-type mice that were given the specific PPARbeta/delta ligand L-165041 before renal ischemia were completely protected against renal dysfunction, as indicated by the lack of rise in serum creatinine and fractional excretion of Na+. This protective effect was accompanied by a significant reduction in medullary necrosis, apoptosis, and inflammation. "
2.	Necrosis 08/01/2005 - "Conversely, wild-type mice that were given the specific PPARbeta/delta ligand L-165041 before renal ischemia were completely protected against renal dysfunction, as indicated by the lack of rise in serum creatinine and fractional excretion of Na+. This protective effect was accompanied by a significant reduction in medullary necrosis, apoptosis, and inflammation. "
3.	Ischemia 08/01/2005 - "Conversely, wild-type mice that were given the specific PPARbeta/delta ligand L-165041 before renal ischemia were completely protected against renal dysfunction, as indicated by the lack of rise in serum creatinine and fractional excretion of Na+. This protective effect was accompanied by a significant reduction in medullary necrosis, apoptosis, and inflammation. "
4.	Insulin Resistance 08/01/2011 - "Administration of L-165041 improved the hepatic steatosis and increased the insulin sensitivity in HFD-mice. "
5.	Cardiomegaly (Heart Hypertrophy) 04/01/2009 - "These data indicate that PPARdelta ligand L-165041 inhibits AngII induced cardiac hypertrophy by suppressing intracellular Ca(2+)/FAK/ERK signaling pathway in a PPARdelta dependent mechanism." 04/01/2009 - "Thus, in the present study, we examined the effect of selective PPARdelta ligand L-165041 on angiotensin II (AngII) induced cardiac hypertrophy and its underlying mechanism using cardiomyocyte. " 03/01/2005 - "Induction of cardiac hypertrophy by PE stimulation also led to a reduction in the transcript levels of both muscle-type carnitine palmitoyltransferase (50%, P<0.05) and pyruvatedehydrogenase kinase 4 (30%, P<0.05), and these changes were reversed in the presence of the PPARbeta/delta agonist L-165041. "

Related Drugs and Biologics

1.	Ligands
2.	PPAR delta
3.	PPAR-beta
4.	Lipids
5.	Creatinine
6.	Angiotensin II
7.	GW 501516
8.	Acetic Acid (Vinegar)
9.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
10.	LDL Receptors (LDL Receptor)